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Introduction
Human α-synuclein is a natively unfolded 140-amino-acid 
residue protein widely expressed in neurons, found predominantly 
in presynaptic terminals.1-3 It was originally identified at the 
nuclear level, accounting for the designation “syn-nuclein”,4 
but subsequently described as a predominantly cytoplasmic 
protein.5-7 While an ultimate definition of α-synuclein function 
has not been provided yet, different studies have shown its 
role in mediating dopamine synthesis, release and reuptake in 
dopaminergic neurons, as strongly suggested by the protein 
presynaptic location and its interaction with membranes.8-13 
Additional studies reported α-synuclein upregulation in 
response to oxidative stress and excitotoxicity, suggesting a role 
for the protein in protecting neuronal cells against damage.14 In 
particular, α-synuclein may cooperate with the cysteine-string 
protein-α (CSPα)—a synaptic vesicle protein with co-chaperone 
activity—in preventing neurodegeneration.15
Structurally, α-synuclein features an N-terminal domain 
(residues 1–60), a central hydrophobic portion denoted as non-Aβ 
component of Alzheimer diseases amyloid (NAC, residues 61–95) 
and a C-terminal negatively charged region (residues 96–140). 
Both the N-terminal and NAC domains contain six highly 
conserved hexameric (KTKEGV) motifs (Fig. 1A and B).16 In its 
native monomeric state, α-synuclein behaves as an intrinsically 
unstructured protein, characterized by the lack of a stable tertiary 
structure.17,18 However, it may adopt a secondary structure upon 
binding to protein interactors or lipid membranes. Early studies 
reported that the N-terminal domain of α-synuclein displays 
α-helical folding in the presence of artificial membranes such 
as sodium dodecyl sulfate micelles.19-22 Solution state NMR 
studies on the structures of micelle-bound α-synuclein have 
shown that the protein contains two distinct α-helices in the 
region encompassing residues 1–92, while the C-terminal 
results predominantly unstructured (Fig. 1C and D).23,24 Other 
studies have attempted to obtain structural information about 
α-synuclein segments complexed with physiological partners 
such as calmodulin25 or synphilin-1,26 with a nanobody27 or 
the maltose binding protein28 (Fig. 1E–H). A recent work has 
reported that natively cell-extracted α-synuclein may be present 
as a tetramer formed by α-helical folded monomers with no 
binding to lipid membranes,29 but a further work has shown that 
α-synuclein in mammalian cells exists as unfolded monomer 
when dissociated from lipid membranes.30
Overall the structural studies on the α-synuclein monomer 
suggest a model where the lack of secondary structure motifs is 
the first event leading to its misfolding and aggregation in patho-
logical and disease-related amyloid assemblies found in Parkinson 
disease (PD) and other synucleinopathies.
In the next sections, we present an overview of the strategies 
currently used to produce synthetic α-synuclein assemblies and 
their possible implications for the future of PD research.
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Aggregation of α-synuclein plays a crucial role in 
the pathogenesis of synucleinopathies, a group of 
neurodegenerative diseases including Parkinson disease 
(PD), dementia with Lewy bodies (DLB), diffuse Lewy body 
disease (DLBD) and multiple system atrophy (MSA). The 
common feature of these diseases is a pathological deposition 
of protein aggregates, known as Lewy bodies (LBs) in the 
central nervous system. The major component of these 
aggregates is α-synuclein, a natively unfolded protein, which 
may undergo dramatic structural changes resulting in the 
formation of β-sheet rich assemblies. in vitro studies have 
shown that recombinant α-synuclein protein may polymerize 
into amyloidogenic fibrils resembling those found in LBs. 
These aggregates may be uptaken and propagated between 
cells in a prion-like manner. Here we present the mechanisms 
and kinetics of α-synuclein aggregation in vitro, as well as 
crucial factors affecting this process. we also describe how 
PD-linked α-synuclein mutations and some exogenous factors 
modulate in vitro aggregation. Furthermore, we present a 
current knowledge on the mechanisms by which extracellular 
aggregates may be internalized and propagated between 
cells, as well as the mechanisms of their toxicity.
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In Vitro Aggregation Assays of α-Synuclein
Deposition of Lewy bodies (LBs) and Lewy neurites (LNs) 
in the brain is a major pathological hallmark of several neurode-
generative diseases, including PD, dementia with Lewy bodies 
(DLB), diffuse Lewy body disease (DLBD), and multiple sys-
tem atrophy (MSA). LBs are spherical cytoplasmic inclusions, 
5–25 µm in diameter, formed by aggregated proteins, with 
a dense eosinophilic core and a clearer surrounding halo. The 
major component of the proteinaceous filaments of LBs and LNs 
is α-synuclein.31
In vitro studies have revealed that recombinant α-synuclein 
can assemble into fibrils with morphologies and staining charac-
teristics similar to those extracted from disease-affected brains. 
Wild-type (WT) α-synuclein fibrils formed in vitro are 8–10 nm 
in height as determined by atomic force microscopy (AFM) and 
about 10 nm in width (electron microscopy, EM), while fibrils of 
PD LBs observed in tissue slices are reported to be about 10 nm 
in width.32-34 Moreover, the presence of “twisted” fibrils as well 
as some small filaments of 5 nm width is a common feature of 
fibrils extracted from brains and some fibrils formed in vitro.31,32
Aggregation of α-synuclein plays a critical role in PD and 
related neurodegenerative disorders; hence in vitro aggregation 
assays are powerful molecular tools for studying the mechanisms 
of neurodegeneration. Understanding the mechanisms by which 
a soluble α-synuclein is transformed into insoluble β-rich fibrils, 
as well as describing the structural features of these fibrils are 
still questions to be addressed in future research. Additionally, 
α-synuclein aggregation assays may be feasible tools for the 
development of new drug compounds capable of interfering with 
α-synuclein fibril formation. Increasing evidence demonstrates 
that in vitro formed fibrils are internalized by cells and may be 
Figure 1. Structural features of monomeric α-synuclein. Primary amino acidic sequence (UniProtKB: P37840) of human α-synuclein with the imperfect 
exapeptide repeats16 underlined (A) and schematic representation of the biochemically different domains including the currently identified PD-related 
mutations (B). Currently available NMR and X-ray crystal structures of α-synuclein segments (in red) bound to micelles (C and D) PDB: 1XQ8 and 2KKw, 
respectively, calmodulin, CaM (E) PDB: 2M55, synphylin-1 (F) PDB: 2JN5, nanobody, NbSyn2 (G) PDB: 2X6M and maltose binding protein (H) PDB: 3Q25, 
2Q26, 3Q27.
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propagated in a prion-like manner leading to cytotoxicity. Thus, 
in vitro aggregation of α-synuclein may yield crucial compo-
nents for studying molecular mechanisms of aggregate uptake, 
spreading and toxicity.
Strategies for the purification of recombinant α-synuclein
In vitro fibrillization assays require high amounts of highly 
pure α-synuclein protein. Recombinant α-synuclein is usu-
ally produced in E. coli cells and purified from either whole 
cell extract or periplasmic extract. Traditionally, the protein is 
purified from the whole cell extract by sonication or boiling, 
or ammonium sulfate precipitation followed by anion exchange 
and size exclusion chromatography purifications.35-37 Ren and 
collaborators have shown that E.coli-expressed α-synuclein with-
out signal sequence mostly localizes in the bacterial periplasm.38 
The protein translocation appeared to be mediated by the sig-
nal recognition particle (SRP)-dependent pathway facilitated 
by the α-synuclein C-terminal domain (residues 90–140) as a 
major part responsible for the translocation.38 Therefore, a new 
efficient and fast method has been developed for α-synuclein 
extraction and purification from periplasm.39 Briefly, the pro-
tein is first extracted from bacterial periplasm by osmotic shock, 
followed by anion-exchange chromatography purification. One 
L of E.coli LB medium culture yields about 80 mg of highly pure 
α-synuclein.39
Tools for monitoring α-synuclein fibril formation in vitro
In vitro fibrillization assays require powerful tools for 
detecting fibril formation and monitoring the fibrillization 
kinetics in real time. Two common histological dyes, Thioflavin 
T (ThT) and Congo red (CR), are used to this end. The 
mechanism of interaction between both dyes and amyloid fibrils 
remains poorly understood; both compounds seem nevertheless 
to interact with the cross-β structures, exhibiting changes in 
fluorescence. ThT is a benzothiazole dye that exhibits enhanced 
fluorescence upon binding to amyloid fibrils and constitutes 
the mostly used extrinsic probe for monitoring fibrillization 
kinetics in vitro. In the presence of fibrils, ThT gives rise to 
an excitation maximum of 450 nm and enhanced emission 
at 482 nm, whereas unbound ThT is not fluorescent at these 
wavelengths.40 ThT is a reliable and specific fibril-detecting 
tool, which does not interfere with the kinetics of α-synuclein 
fibrillization.41 However, despite its specificity toward fibrils, 
a slight increase in ThT fluorescence has been detected after 
binding to amorphous α-synuclein aggregates.42 The use of 
ThT for monitoring fibril formation should be optimized and 
negative controls are needed, as spectral properties of this dye 
may vary under different conditions. Additionally, being ThT a 
charged and hydrophobic molecule, it may non-specifically bind 
to some proteins by electrostatic and hydrophobic interactions.43
CR seems unsuitable for monitoring α-synuclein aggrega-
tion, since it exhibits high affinity binding to α-synuclein and 
has an inhibitory effect on the fibrillization assay.44 Some studies 
have indicated that CR may interfere with protein misfolding 
and aggregation by stabilizing native protein monomers or par-
tially folded intermediates.45
Since the sensitivity and specificity of ThT and CR have 
been questioned, several efforts have been made to design 
extrinsic probes and spectroscopic techniques for monitoring 
the fibrillization process. Celej and coworkers reported that 
N-arylaminonaphthalenesulfonate (NAS) and its derivatives 
act as non-covalent, highly sensitive probes of α-synuclein fibril 
formation.46 Recently, it has been shown that protein aggre-
gation reactions can be spectroscopically monitored without 
the need for extrinsic labels. Some studies have reported that 
amyloid-like structure is associated with an intrinsic fluo-
rescent phenomenon that occurs in the visible range.47-49 The 
physical mechanism underlying the intrinsic fluorescence emis-
sion remains unknown. It has been suggested that the hydro-
gen-bonded water molecules within the cross-β structure might 
play a key role in the fluorescence emission of the fibrils. Direct 
excitation of the fibrils could induce electronic transitions in 
peptides because of a partial delocalization of peptide electrons 
elicited by the presence of hydrogen bonds.47 Pinotsi and col-
laborators have shown that this phenomenon can be used for 
monitoring the aggregation of proteins with no need for extrin-
sic labels, thus avoiding potential interference with the aggrega-
tion process.50 This method appears feasible and reproducible; it 
requires a confocal microscope and it has been successfully used 
for monitoring α-synuclein fibrillization in vitro.50
Mechanism and kinetics of fibril formation in vitro
During the fibrillization process, a soluble protein is con-
verted into insoluble highly ordered aggregates exhibiting 
β-sheet enriched structures. Fibrillization of globular proteins 
requires the presence of partially unfolded conformations in 
order to adopt a structure competent for self-assembly into 
fibrils.51 Partial unfolding exposes the hydrophobic regions of 
the protein, thus facilitating the interactions between exposed 
amyloidogenic regions of two proteins and subsequent formation 
of higher order species. Several factors destabilizing the native 
fold of the protein, such as mutations, denaturants, changes in 
pH, or elevated temperature, have been shown to enhance fibril 
formation.51
Fibrillization of natively unfolded proteins such as 
α-synuclein presents intriguing issues, since it remains unclear 
how an intrinsically unstructured protein may form highly orga-
nized β-structured fibrils. Partial folding of the protein seems to 
represent a crucial step in the fibrillization pathway.51 Natively 
unfolded proteins are characterized by low hydrophobicity and 
a large net charge.52 It is supposed that any factors increasing 
protein hydrophobicity or decreasing protein net charge may 
lead to its partial folding and thus promote the fibrillogenic 
pathway. The overall hydrophobicity of a protein increases with 
higher temperature.53 It has been reported that either a decrease 
in pH or an increase in temperature leads α-synuclein to adopt 
a partially folded conformation, a change correlated with the 
enhanced formation of fibrils.41
The model for α-synuclein fibrillization has been proposed 
as follows:
U ↔ I ↔ nucleus → F,
where U corresponds to natively unfolded conformation; 
I, partially folded intermediate; nucleus, fibril nucleus; and 
F, fibril. This model describes the two key kinetic steps in 
the fibrillization process. The first step is the conformational 
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transformation of α-synuclein into the aggregation-competent, 
partially folded intermediate; the second is the formation of the 
assembly-competent oligomers (nuclei), which is followed by 
oligomer growth and fibril formation. The model suggests that 
any factor that promotes intermediate formation (for example 
point mutations, non-polar molecules, cations, and others) will 
also promote α-synuclein fibrillization.41
The kinetics of α-synuclein fibrillization is commonly 
described as a sigmoidal curve, composed of an initial lag phase 
(nucleation) when the amount of fibrils is too low to be detected, 
a subsequent exponential phase (elongation) when fibril concen-
tration increases rapidly, and a final plateau phase indicating the 
end of fibril formation. The length of lag phase and the fibril 
growth rates depend on several factors, including initial protein 
concentration, pH, temperature, agitation and other factors that 
will be discussed below.
Moreover, the fibrillization process can be catalyzed by add-
ing preformed fibrils (seeds), which act as nuclei.54-56 This effect 
has been termed “‘nucleation-dependent’ fibrillization.” The 
added seeds may act as catalytic sites that induce conformational 
changes in α-synuclein and accelerate the reaction rates.54
To compare the effects of different reaction conditions on 
fibrillization kinetics, ThT fluorescence is commonly plotted 
as a function of time and fitted to a sigmoidal curve using the 
equation: 
where Y is the fluorescence intensity, x is the time, and x
0
 is the 
time to 50% of maximal fluorescence. Thus, the apparent rate 
constant, k
app




To test the effects of different factors on fibrillization kinet-
ics, usually the lag phase, the apparent rate constant and/or the 
maximum intensity of ThT emission intensity at the end of fibril 
formation are calculated. These values obtained from tested sam-
ples are compared using commonly available statistic tests.58 The 
fibrillization kinetics has been shown to be fairly similar among 
different amyloidogenic proteins. However, the kinetic profiles 
do not display always the typical sigmoidal shape since multiple 
steps may be present, thus affecting the interpretation of the cor-
rect lag phase and the apparent rate constant. Optimizing the 
reproducibility of protein fibrillization is crucial to obtain reliable 
results.58
Various data confirmed that in vitro aggregation of α-synuclein 
may yield different final products, such as fibrils, soluble oligo-
mers, or insoluble “amorphous aggregates.” Aggregation assays 
resulted in the formation of several oligomeric species with dif-
ferent morphologies, including spherical, chain-like, and annular 
oligomers.59 However, the mechanism of conversion among dif-
ferent oligomers is not fully understood.
The generation of different α-synuclein conformations has 
also been associated with the pathogenesis of PD and other synu-
cleinopathies; fibrillar forms seem nevertheless to be the main 
component of LBs.31
Structural features of human α-synuclein fibrils
The assembly of physiologically expressed proteins into 
oligomeric and fibrillar aggregates with cross-β structure is an 
essential event of different human neurodegenerative diseases, 
such as PD, Alzheimer disease, and prion diseases. It is generally 
accepted that aggregation takes place from partially structured 
states of proteins. However, the role of the residual structures 
present in such conformational states is not well understood. 
α-synuclein fibrillar aggregates are pathological hallmarks of 
PD and other related synucleinopathies. The structural organi-
zation of α-synuclein amyloid fibrils has been researched exten-
sively. Amyloid fibrils are composed of several protofilaments 
arranged into the classical cross-β conformation, with indi-
vidual β-strands running perpendicular to the fiber axis.34,60,61 
Findings from electron paramagnetic resonance (EPR)62,63 and 
magic-angle spinning solid-state NMR (ssNMR) have shown 
that the amyloidogenic β-sheet core is mostly located within 
the central NAC domain.64-71 Figure 2 illustrates an updated 
view of the β-sheet organization into the α-synuclein amyloid 
fibrils as determined by ssNMR. Although the fibril core spans 
approximately residues 38 to 100, structural variations of local 
β-strands have been reported inside this region. A recent report 
has expanded current knowledge of the α-synuclein segments 
involved in amyloid structural reorganization. In particular, 
Bousset and collaborators identified two novel α-synuclein 
assemblies characterized by ordered β-sheet organization start-
ing from residue 1 to 38; this region appeared unstructured 
in all previous ssNMR studies.65 Interestingly, the same group 
has reported that the two α-synuclein polymorphs showed 
marked differences in their biological functions. Overall the 
EPR and ssNMR studies highlight the remarkable confor-
mational plasticity of α-synuclein, which can adopt different 
monomeric, oligomeric, or fibrillar assemblies depending on 
the environment.
Factors affecting the kinetics of α-synuclein fibrillization 
in vitro
Oligomers and fibrils produced in vitro under diverse con-
ditions may result in different structural properties and con-
sequently exert different biological functions.72 As mentioned 
above, several factors including the initial concentration of 
monomeric protein, molecular crowding, agitation, pH, tem-
perature, and ionic strength, have been shown to greatly affect 
the kinetics of α-synuclein fibrillization.32,41,73-75 Thus, develop-
ing a reliable and reproducible aggregation assay is necessary 
to screen the effects of exogenous factors on the fibrillization 
process, as well as to produce different aggregate species for 
structural studies and test their biological functions. Here, we 
characterize crucial factors that determine the kinetics of fibril 
formation in vitro.
α-synuclein concentration
Initial concentration of monomeric α-synuclein is a crucial 
factor determining the kinetics of fibril formation. Commonly, 
0.5 to 1 mg/mL (35–70 µM) of α-synuclein is used during fibril-
lization assays.39,74,76,77 Other studies have used higher concen-
trations, namely 5 to 7 mg/mL.78,79 The minimal α-synuclein 
concentration, below which fibrils are not formed, has been 
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estimated to be approximately 0.2 mg/mL.80 The kinetics of 
fibril formation is a concentration-dependent process; however, 
the concentration dependence almost disappears in the pres-
ence of higher protein concentrations. Above the supercritical 
concentration, nucleation is no longer rate-limiting and the 
fibril growth rate is almost independent of the protein con-
centration.81 In fact, increasing α-synuclein concentration 
has been reported to decrease the lag-phase of fibrillization.82 
Supercritical concentration of α-synuclein has been estimated 
to be about 8.2 mg/ml (~ 574 µM); however this may vary 
according to the conditions used for the fibrillization reaction.42
Molecular crowding
Macromolecular crowding is another factor significantly 
affecting aggregation, as it may dramatically accelerate 
α-synuclein fibril formation.74,83 The effect of molecular crowd-
ing on protein aggregation in vitro has been examined by using 
concentrated solutions of a model “crowding agent” such as poly-
ethylene glycols (PEG), polysaccharides (dextrans or Ficolls), or 
proteins (for example, lysozyme and bovine serum albumin). All 
these molecules accelerated α-synuclein fibrillization in vitro.83 
The crowding agents had little effect on the conformation of 
α-synuclein, as shown by far-UV CD spectroscopy.74 It seems 
that the mechanism by which crowding agents affect fibrilliza-
tion depends on their concentrations. It has been suggested that 
at lower crowding agent concentrations, the major effect of mac-
romolecular crowding on protein aggregation is due to excluded 
volume effect, which favors self-association of α-synuclein 
following the increase of the effective protein concentration. At 
a higher concentration, viscosity effects of the polymer solutions 
may become dominant.74
Agitation
As reported by several studies, agitation is yet another 
crucial factor impacting the kinetics of the fibrillization process. 
Agitation of α-synuclein solutions leads to a dramatic increase 
in the rate of fibrillization, shortening the lag phase from weeks 
to hours.32,84 Uversky and collaborators have reported that vigor-
ous agitation was the major determinant of the fibrillization rate. 
Very vigorous agitation attenuated the effects of ionic strength, 
protein concentration and various additives on the rate of fibril 
formation.85 The exact mechanism by which agitation induces 
fibrillization is unknown, however it could increase the air-water 
interface, thus leading to a partial folding of α-synuclein and the 
formation of the fibrillization intermediate.82 Moreover, agitation 
may increase the number of fibril ends through fragmentation or 
increase the collision of monomeric and oligomeric species inter-
acting with fibril ends.86
Agitation is commonly performed either in a glass vial with 
a mini stir bar or in microplates on a fluorescence plate reader. 
With the former method, termed single time-point dilution ThT 
assay,39,41,75,87,88 aliquots are taken out at given time intervals for 
ThT fluorescence measurement, whereas in the latter approach 
(in situ real-time assay) ThT fluorescence is monitored in real-
time at regular intervals.58,73,74 Agitation speed in different assays 
ranges from 120 rpm89 to 1000 rpm.78 Agitation with glass beads 
has been shown to significantly decrease the lag time of the fibril-
lization and to increase the reproducibility of the assay.58
Figure 2. α-synuclein fibril core regions as determined by ssNMR studies. Upper panel: schematic representation of the α-synuclein segment from 
residue 1 to 100 involved in structural changes. Lower panel: proposed β-strand (indicated as red pentagons) organization of different human (Hu) 
α-synuclein fibrillar assemblies determined by different groups: (A) reference 68 (B) reference 67 (C) reference 69 (D) reference 70 (E) reference 71 
(F) reference 65.
24 Prion volume 8 issue 1
Reproducibility is an important issue in in vitro fibrillization 
assays, as it may vary significantly across sample replicates and 
among experiments.58 Giehm and Otzen have tested factors that 
influence the reproducibility of the fibrillization of α-synuclein 
in plate reader assays. The authors have determined that increased 
reproducibility is correlated with decreased lag time. Orbital agi-
tation using a small glass bead in each well significantly increased 
lag time and was crucial to obtain good reproducibility.58
Temperature, pH, and ionic strength
Several data have indicated that decreasing the pH or increas-
ing the temperature substantially accelerated the kinetics of 
α-synuclein fibrillization, affecting both the lag time and the 
elongation rate. Elevated temperatures have been shown to 
strengthen hydrophobic interactions whereas lower pH decreased 
the net charge of the protein.41,53 Both factors induced some struc-
tural changes in α-synuclein, as shown by far-UV CD and FTIR 
spectroscopies, and consequently contributed to a reversible 
transformation of α-synuclein into a partially folded intermedi-
ate, whose formation is crucial for the fibrillization process.41,75
The rate of fibril formation has been shown to increase 
dramatically with increasing ionic strength, reaching the maximal 
effect by 300 mM NaCl. Anions have been suggested to induce 
partial folding of α-synuclein at neutral pH, thus increasing 
the population of the amyloidogenic intermediate. CD spectra 
confirmed that at 20 mM concentration, different salts induced 
partial folding of α-synuclein.73
Exogenous factors modulating α-synuclein fibrillization 
in vitro
Although the specific etiology of PD is unknown, several 
factors, both genetic and environmental, may increase the risk of 
developing the disease.90 In vitro aggregation assays are easy, fast, 
and powerful tools for screening potential factors that may affect 
α-synuclein aggregation and thus contribute to PD pathogenesis. 
Several studies have reported that α-synuclein aggregation may 
be triggered by environmental and other exogenous factors, 
such as pesticides, heavy metals, polycations, organic solvents, 
and some small chemical compounds.91,92 Here, we briefly 
characterize factors that have been shown either to accelerate or 
inhibit α-synuclein aggregation in vitro. Table 1 summarizes 
exogenous factors that have been involved in the modulation of 
α-synuclein aggregation.
Pesticides and herbicides
Uversky and collaborators have reported that certain pesti-
cides and herbicides (rotenone, dieldrin, and paraquat) dramati-
cally accelerated the rate of fibril formation in vitro.85 It has been 
suggested that the relatively hydrophobic pesticides may bind to 
the partially folded α-synuclein intermediate, induce its confor-
mational changes and consequently lead to fibril formation.85 In 
fact, epidemiological studies have shown increased risk of PD in 
populations exposed to pesticides.93,94
Polycations
Polycations, such as spermine, polylysine, polyarginine, and 
polyethylenimine, dramatically accelerated α-synuclein fibrilliza-
tion in vitro. α-synuclein-polycation complex formation was not 
accompanied by significant structural changes in α-synuclein.77 
Electrostatic interactions between polycations and α-synuclein 
have been suggested to lead to neutralization of the protein net 
negative charge and to the partially folded amyloidogenic inter-
mediate that initiates fibril formation.77
Metal ions
Several works have described how some metal ions affected 
α-synuclein fibrillization in vitro. Di- and trivalent ions (e.g., 
copper, iron, cobalt, and manganese) accelerated the rate of fibril 
formation. Metal ions stimulated α-synuclein conformational 
change and led to the development of a partially folded interme-
diate, a possible critical precursor of fibrils.76,95 Metal exposure 
has been suggested as one of the factors that may increase the 
risk of PD. Several epidemiological studies have shown that expo-
sure to some metals, including manganese, iron, aluminum, and 
copper, was associated with a higher risk of PD.96-99 Moreover, 
elevated levels of iron, zinc, and aluminum have been reported 
in the substantia nigra of PD patients, thus confirming their 
involvement in the pathogenesis.100-102
Histones
Some histones have been shown to form a tight complex with 
α-synuclein and accelerate its fibrillization in a dose-dependent 
manner.103 This effect may be physiologically important, as the 
translocation of α-synuclein into the nucleus and its binding to 
histones may play a large role in α-synuclein pathology.
Small chemical compounds
Many therapeutic strategies for PD aim at develop-
ing chemical compounds and small molecules capable of 
inhibiting fibril formation. Masuda and collaborators have 
tested 79 small compounds belonging to different chemical 
classes (including polyphenols, benzothiazoles, phenothia-
zoles, steroids, Congo red and its derivatives) for their ability 
to inhibit the assembly of α-synuclein into filaments in vitro.44 
Several of these compounds inhibited α-synuclein assembly; 
among them, polyphenols proved to be an especially effective 
class of anti-aggregation compounds. The mechanism under-
lying the polyphenol-induced inhibition is unclear, but these 
compounds seem to stabilize soluble, prefibrillar intermedi-
ates.44 Meng and coworkers have tested 48 compounds repre-
sentative of different classes of f lavonoids for their ability to 
inhibit α-synuclein fibril formation in vitro. A variety of f la-
vonoids inhibited α-synuclein in vitro fibrillization to varying 
extents: some of them (myricetin, tricetin, 6-HP and baicalein) 
completely inhibited fibril formation and many were able to 
disaggregate preformed fibrils.104
Heat shock proteins
Heat shock proteins (Hsp) have been reported to interact 
with α-synuclein and inhibit its aggregation in vitro.105-108 The 
small Hsp αB-crystallin, a molecular chaperone, inhibited 
α-synuclein fibrillization. The interaction of α-synuclein with 
αB-crystallin resulted in large irregular aggregates, suggest-
ing that the chaperone protein redirected α-synuclein from a 
fibril-formation pathway toward an amorphous aggregation 
pathway.105 Hsp70 protein inhibited α-synuclein filament for-
mation by binding to soluble prefibrillar intermediates.106,107 
Moreover, different Hsp proteins (HspB8, Hsp27, HspB2B3, 
and αB-crystallin) inhibited the α-synuclein aggregation 
process, as shown by ThT assay and AFM imaging.108
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PAMAM dendrimers
Another class of compounds exerting anti-aggregation effects 
includes polyamidoamine (PAMAM) dendrimers—highly 
branched polymers possessing a well-defined spherical geom-
etry.109 PAMAM dendrimers (generations G3, G4, and G5) 
inhibit fibrillization of α-synuclein and promote the breakdown 




Pesticides (rotenone, dieldrin, paraquat) bound to the partially folded intermediate conformation of 
α-synuclein and induced its conformational changes to β-sheet enriched structures.
85,89
Polycations
α-synuclein bound to different polycations (spermine, polylysine, polyarginine, polyethyleneimine) 
forming stable complexes. Complex formation did not cause significant changes in α-synuclein 
secondary structures, as shown by far-Uv CD spectroscopy.
77
Histones
Bovine histone H1 and bovine core histones (a mixture of H2a, H2b, H3 and H4) accelerated α-synuclein 
fibrillization in a dose-dependent manner. The formation of α-synuclein-histone complexes was not 
accompanied by significant changes in either secondary structure (CD) or globular structure (SAX).
103
Metal ions
Several divalent and trivalent ions (copper, iron, cobalt and manganese) accelerated α-synuclein 




Some glycosaminoglycans (heparin, heparin sulfate, agrin) and other highly sulfated polymers (dextran 
sulfate) significantly accelerated the formation of α-synuclein fibrils in vitro. Binding to α-synuclein 
induced conformational changes of the protein.
87,157
Sodium dodecyl sulfate
SDS stimulated α-synuclein fibrillization in a highly reproducible manner. SDS-induced fibrils did 




Organic solvents affected fibrillization kinetics in a concentration-dependent fashion. Low 
concentrations of alcohols accelerated the rate of fibrillization, whereas at high concentrations the 
effect was dependent on the type of alcohol—simple alcohols induced β-helix-rich conformation, 
fluorinated alcohols promoted α-helix-rich species. All solvents induced folding of α-synuclein, as 




Different chemical classes of compounds have been shown to inhibit α-synuclein fibrillization in vitro 
(polyphenols, benzothiazoles, phenothiazoles, steroids, Congo red and its derivatives, flavonoids). 
Some of them were able to disaggregate the preformed fibrils.
44,104
Heat shock proteins (Hsp)
Small Hsp proteins (αB-crystallin, HspB8, Hsp27, HspB2B3) inhibited α-synuclein fibrillization. The 
formation of aggregates suggested that Hsp proteins may redirect α-synuclein from a fibril-formation 
pathway toward an amorphous aggregation pathway.
Hsp70 inhibited α-synuclein filament formation by binding to soluble prefibrillar intermediates.
105-108
PAMAM dendrimers
PAMAM dendrimers (generations G3, G4, and G5) inhibited fibrillization of α-synuclein and promoted 
the breakdown of pre-existing fibrils. They induced structural changes in α-synuclein and redirected the 
protein to an amorphous aggregation pathway.
109
β- and γ-synucleins
β- and γ-synucleins increased the lag time and dramatically reduced the elongation rate  




Several catecholamines, including L-DOPA and dopamine, were able to inhibit α-synuclein fibrillization 
and to dissolve the preformed fibrils in vitro.
160
Phospholipids Acidic phospholipids induced α-helical structure in α-synuclein, thus preventing the formation of fibrils. 161
Rifampicin
Rifampicin inhibited α-synuclein fibrillization and disaggregated existing fibrils by stabilizing 
monomeric and soluble oligomeric forms.
162
Trehalose




Oxidation of α-synuclein methionines, N-terminal acetylation, and Tyr-nitration 
have been reported as protective factors against fibrillization.
164-166
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of pre-existing fibrils. They have been shown to induce struc-
tural changes in α-synuclein and redirect the protein to an 
amorphous aggregation pathway.
Organic solvents
Some factors affecting α-synuclein fibril formation have 
been reported to inhibit or accelerate the fibrillization depend-
ing on their concentration or reaction conditions. Munishkina 
and collaborators have tested the effect of different organic 
solvents on α-synuclein fibrillization kinetics.73 Far-UV CD, 
FTIR and MS spectra confirmed that they induced folding 
of α-synuclein.73,95 The concentration and composition of dif-
ferent alcohols (ethanol, methanol, and propanol) differently 
affected the fibrillization rate of α-synuclein.73 Notably, recent 
studies have established that overexpression of α-synuclein and 
the consequent higher risk for developing PD is modulated by 
chronic long-term alcohol exposure.110,111
Effect of PD-related mutations on α-synuclein fibrillization 
in vitro
Three autosomal dominant missense point mutations in 
the SNCA gene have been identified in early-onset PD: A53T, 
A30P, and E46K.112-114 Recently, two independent groups have 
discovered the novel pathogenic mutation H50Q.115,116 Several 
works have shown that PD-linked mutations A53T, A46K, 
and H40Q promoted α-synuclein aggregation in vitro, yet 
neither of them affected the overall structure of the α-synuclein 
monomer.32,75,115-120
Mutations A53T and E46K have been shown to significantly 
accelerate fibrillization in vitro when compared with WT pro-
tein.117 Although the A53T and E46K mutated α-synuclein 
fibrils exhibited distinct morphologies, the rate of amyloid 
formation of both mutants was similar.121,122 A53T fibrils were 
about 5–14 nm in width and appeared twisted, with a cross-
over spacing of about 100 nm; E46K fibrils had often a twisted 
appearance too, with width varying between about 5 and 
14 nm, but with shorter crossover spacing of about 43 nm.121 
Recently, Lemkau and collaborators have found by ssNMR that 
both mutated fibrils possessed site-specific perturbations in 
their secondary structures, which could alter the overall struc-
tural arrangement of the fibril.123
Similarly to WT α-synuclein protein, both mutants gener-
ated also prefibrillar intermediates with pore-like activity.60,118,124
The effect of the A30P mutation on fibrillization is not 
clear, as some data reported that it formed fibrils slightly faster 
than WT protein,37 whereas others showed that this mutation 
decreased fibril formation.60,125 Conway and collaborators have 
observed that A30P had a slower propensity to form fibrils 
than WT, and it preferentially adopted a soluble, protofibril-
lar conformation, whereas the WT protein readily progressed 
to mature fibrils.60 In spite of that, some data have shown that 
A30P fibril morphologies were similar to those formed from 
WT protein.34,121 Both WT and A30P fibrils had a filament 
width of 6–9 nm, which varied slightly along the length of the 
filaments.121
The recently identified H50Q mutant has been shown to 
aggregate more readily than WT protein, but more slowly than 
A53T and E46K.120 AFM studies have shown that, similarly to 
WT protein, the H50Q protein oligomerized through small 
oligomers, from protofibrils to mature fibrils.120
Current Knowledge on Internalization  
and Propagation of α-Synuclein Aggregates
Increasing evidence argues that α-synuclein may transfer 
from cell to cell, suggesting that prion-like propagation may 
mediate the pathological progression of PD. Braak and colleagues 
have proposed that α-synuclein pathology begins in the lower 
brainstem and olfactory bulb and spreads into the limbic sys-
tem and eventually to the cortex.126 Two independent studies 
have revealed host-to-graft propagation of α-synuclein-positive 
Lewy-like pathology, providing further evidence for prion-like 
spreading of the pathology.127,128 Embryonic mesencephalic 
neurons grafted into the neostriatum of PD patients have been 
shown to accumulate LB pathology. Moreover, α-synuclein was 
transmitted via endocytosis to neighboring neurons, forming 
Lewy-like inclusions. α-synuclein was also transmitted from the 
affected neurons to engrafted neuronal precursor cells in a trans-
genic (Tg) model of PD-like pathology.129
Several recent studies have investigated whether α-synuclein 
aggregates formed in vitro from recombinant protein may be inter-
nalized by cells and eventually recruit endogenous α-synuclein 
to form LB-like pathology. Increasing evidence suggests that 
misfolded α-synuclein aggregates, both fibrils and oligomers, 
may be uptaken and propagated among cells in a prion-like man-
ner and induce pathology in healthy cells.78,79,129,130
Luk and collaborators have shown that addition of in vitro 
preformed α-synuclein fibrils into culture medium induces intra-
cellular α-synuclein aggregation in different cell lines overex-
pressing this protein.78 The fibrils were shown to rapidly recruit 
endogenous soluble protein converting this into detergent-insol-
uble inclusions, while monomeric and oligomeric α-synuclein 
showed only a negligible effect. Moreover, α-synuclein inclu-
sions undergo several modifications characteristic for LBs, such 
as hyperphosphorylation, ubiquitination and accumulation of 
cytoplasmic vesicles around the periphery of the inclusions.78 
Morphological and biochemical similarities between intracellular 
inclusions and LBs suggest that fibrillar seeds may have a central 
role in the initial formation of LBs and other disease-associated 
inclusions. Luk et al. also tested whether exogenous aggregates 
could induce aggregation of endogenous α-synuclein expressed 
by primary cells not overexpressing the protein.131 In fact, 
preformed fibrils entered primary hippocampal neurons and 
promoted recruitment of soluble α-synuclein into insoluble 
LB-like aggregates. Consistent with previous results, endog-
enous aggregates were hyperphosphorylated and ubiquitinated, 
confirming their LB-like properties. Moreover, formation of 
endogenous aggregates resulted in the decrease of some synaptic 
proteins, impairments in neuronal excitability and connectivity 
and, eventually, neuron loss.131
Another study has shown that intracerebral inoculations of 
symptomatic mouse brain lysates or preformed α-synuclein fibrils 
into Tg asymptomatic mice overexpressing the human A53T 
mutant triggered PD-like pathology and dramatically reduced 
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the survival time of animals.132 PD-like pathology was shown 
to spread to distal CNS regions. The most severe α-synuclein 
pathology was detected in brain regions that project to, or receive 
input from the inoculation sites, suggesting that the propagation 
of pathology occurs between associated neuronal populations.132 
Furthermore, intrastriatal inoculation of synthetic α-synuclein 
fibrils into wild-type non-Tg mice also led to cell-to-cell trans-
mission of pathologic α-synuclein and LB-like pathology. The 
α-synuclein pathology caused progressive loss of dopamine 
neurons in the substantia nigra pars compacta and impairment in 
motor coordination.130
Injections of in vitro preformed human or mouse α-synuclein 
fibrils in the substantia nigra of non-Tg mice have also induced 
LB-like pathology, while mice injected with soluble α-synuclein 
did not exhibit pathological symptoms.133 Exogenously injected 
fibrils could be detected for less than one week, but induction 
of α-synuclein pathology was observed after three months. 
The pathology induced by exogenous fibrils was similar to 
that triggered by intracerebral injection of sarcosyl-insoluble 
α-synuclein from brains of patients with DLB.79
Sacino and collaborators have obtained similar results.134 
They have observed that neonatal cerebral injections of exog-
enous α-synuclein fibrils induced pathology after prolonged 
incubation times. The injected α-synuclein was rapidly cleared 
within a few days and inclusion pathology, which arose from 
endogenous protein, was developed after months. Tg mice over-
expressing α-synuclein were more prone to develop pathology. 
Moreover, the authors have shown that injections of the non-
amyloidogenic form of α-synuclein (Δ71–82) induced similar 
pathology, suggesting that the pathogenesis might be induced 
not solely by conformation-dependent templating events.134
Altogether these data strongly confirm that exogenous 
α-synuclein amyloid fibrils produced from recombinant pro-
tein have prion-like properties, as they are sufficient to seed and 
induce pathology in vivo.
A typical hallmark of prion diseases is the existence of 
different “strains,” arising from the same proteins but 
having different incubation periods, PrPSc distribution 
and lesion profiles in the brain, as well as different protease 
cleavage patterns.135 The existence of different strains has not 
been identified so far for other neurodegenerative diseases. 
Recently, Bousset and collaborators have generated in vitro two 
different high-molecule assemblies of α-synuclein, prepared in 
buffers with different salt concentrations.65 These assemblies, 
designated fibrils and ribbons, adopted different conformations, 
as confirmed by transmission electron microscopy (TEM), 
FTIR, X-ray diffraction, and ssNMR. Moreover, proteinase-K 
digestion revealed different cleavage profiles. Fibrils and ribbons 
exhibited marked differences in their propensity to bind and 
penetrate cells, toxicity and seeded aggregation of endogenous 
α-synuclein in vivo. Moreover, they imprinted their intrinsic 
structure to endogenous α-synuclein, suggesting that different 
strain-like assemblies may account for the development and 
progression of different synucleinopathies.65
The mechanism by which exogenous aggregates may be 
internalized by cells is not clear. Previous studies on fibrils 
comprised of polyglutamine repeats and tau proteins have 
shown that exogenous fibrils can be internalized by cells by 
simple addition into culture medium.136,137 Some studies have 
reported that a similar internalization process occurs also for 
α-synuclein,72,129,138 while others have shown that fibrils were 
efficiently introduced into cells only in the presence of a trans-
duction reagent.56,78 Transduction was performed using cat-
ionic-liposomal protein transduction reagent or lipofectamine 
reagent.56,139
Thus the ability of α-synuclein aggregates to enter into cells 
and induce aggregation of endogenous protein may depend on 
the precise structure of the aggregated protein. Danzer and 
collaborators have observed that, depending on in vitro aggre-
gation conditions, α-synuclein oligomers formed distinct popu-
lations that differed in their biophysical properties and cellular 
effects.72,140 Only some types of oligomers were internalized by 
primary neuronal cells and neuronal cell lines, and induced 
endogenous α-synuclein aggregation, while others induced cell 
death via disruption of cellular ion homeostasis.72,140
Another study has confirmed that the mechanism of inter-
nalization and propagation may depend on the assembly state 
of the protein: oligomers and fibrils were uptaken into cells via 
endocytosis, while the monomeric protein passively crossed the 
plasma membrane.138 Internalization of fibrillar α-synuclein 
required physiological temperatures and dynamin-1 activ-
ity, which were necessary for endocytosis. Moreover, it has 
been suggested that extracellular fibrils were internalized by 
receptor-mediated endocytosis. Internalized aggregates moved 
through the endosomal pathway and were degraded by lyso-
somes.138 Internalization of α-synuclein preformed fibrils was 
increased by the presence of wheat germ agglutinin, which 
bound N-acetyl-glucosamine and sialic acids at the cell sur-
face and induced adsorptive-mediated endocytosis, suggesting 
that some glycoproteins might be important players in fibril 
internalization.131
Once α-synuclein aggregates reach acceptor cells, they could 
seed aggregation of endogenous protein in a prion-like fashion 
and eventually the newly formed aggregates may be released 
into the extracellular space. Vesicle-mediated exocytosis could 
be responsible for release of α-synuclein aggregates. Multiple 
forms of α-synuclein have been detected in the cerebrospinal 
fluid, blood plasma and saliva, suggesting an underlying secre-
tory process.141 It has been shown that cultured neuronal cells 
secreted α-synuclein monomers and aggregates by non-classical 
vesicle-mediated exocytosis. Moreover, the secretion was elevated 
in response to proteasomal and mitochondrial dysfunctions asso-
ciated with PD pathogenesis.142
Recently, it has been reported that fibrillar α-synuclein was 
transferred along axons through anterograde axonal transport, 
released, and subsequently uptaken by additional neurons. The 
axonal transfer of fibrils may explain the spread of LB between 
anatomically connected brain areas.143
Moreover, tunneling nanotubes (TNTs) have been suggested 
to play a major role in the propagation of α-synuclein pathol-
ogy. TNTs are tubular membrane bridges interconnecting cells 
over long distances, thus enabling the exchange of molecules and 
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cytoplasmic content between cells.144 TNTs could be involved in 
the intracellular propagation of PrPSc.145 Till now, TNTs have not 
been implicated in PD but their involvement in the spread of 
α-synuclein pathology cannot be ruled out.
Toxicity of α-Synuclein Aggregates
An increasing number of studies, both in vitro and in vivo, 
have suggested that prefibrillar oligomers and protofibrils, rather 
than mature fibrils, may feature toxic species of α-synuclein and 
may cause neuronal injury and cell death.146-149 The process of 
fibril formation, rather than the fibrils themselves, has been sug-
gested as a key element in α-synuclein toxicity. The presence of 
some α-synuclein prefibrillar species may indicate an attempt 
by neurons to convert toxic oligomers to fibrils, which are more 
stable, less dynamic structures and exhibit reduced toxicity.147
Membrane permeabilization by oligomeric species represents 
a potential mechanism of α-synuclein mediated cytotoxicity. 
Monomeric α-synuclein was found to bind negatively charged 
phospholipid membranes and undergo the structural transi-
tion into α-helix.150,151 It has been shown that the protofibril-
lar α-synuclein species binds negatively charged vesicles more 
strongly than the monomer. Moreover, protofibrillar species, 
but not monomeric protein or fibrils, have permeabilized neg-
atively charged vesicles to calcium.150 Two PD-linked variants, 
A53T and A30P, show greater permeabilizing activity than WT 
protein, while this activity is reduced for E46K.118,124
The mechanism of membrane permeabilization is not clear, 
but protofibrillar oligomers have been suggested to permeabilize 
membranes in a pore-like fashion.124 They may integrate into 
the membrane, creating pores or channel-like structures causing 
uncontrolled membrane permeability. Alternatively, oligomers 
or protofibrils could increase the conductivity of the membrane 
without the formation of pores.152
Membrane permeabilization may initiate several pathological 
events leading to changed ion homeostasis, induction of oxidative 
stress, altered signaling pathways, dysfunction of mitochondria, 
inflammation and eventually cell death.153 In fact, several works 
have found that exogenous oligomers led to an increase in intra-
cellular Ca2+ level, diminished levels of some synaptic proteins, 
production of reactive oxygen species and cell death.131,149,150,154 
Moreover, in mice intracerebro-ventricular injections of 
α-synuclein oligomers increased the activity of calcineurin, a key 
negative regulator of synaptic plasticity and memory function, 
thus resulting in a decrease of synaptic plasticity and memory 
deficits.149
It seems that toxicity of α-synuclein oligomers may depend 
on their structure. Danzer and collaborators developed novel 
methods for generating different α-synuclein oligomeric species, 
which have been tested for their biological effects on SH-SY5Y 
cells.72 Only spherical oligomers, 2 to 6 nm in height, increased 
intracellular calcium level and led to caspase-3 activation, sug-
gesting that some structural properties of oligomeric α-synuclein 
may be important to induce toxicity.72 Moreover, Bousset and 
collaborators have tested the toxicity of two α-synuclein assem-
blies (fibrils and ribbons) with different structural properties:65 
fibrils resulted more toxic than ribbons. In fact, fibrils induced 
activation of caspase-3, production of ROS and permeabilized 
lipid vesicles to a higher extent than ribbons.65
Although large sets of data suggest that prefibrillar assemblies 
represent toxic species of α-synuclein, it has been shown that a 
homogenous population of fibrils, rather than their precursor 
on-assembly pathway oligomers, is highly toxic to cells.155 Fibrils 
have been shown to permeabilize membrane vesicles and to alter 
calcium homeostasis. Moreover, cells exposure to increasing 
concentrations of fibrils resulted in the activation of caspase-3 in 
a concentration-dependent manner and cell death, whereas oligo-
meric α-synuclein did not affect cell viability and did not activate 
caspase-3. The authors argued that the discrepancy with previous 
results on oligomer toxicity originates from the comparison of 
protein particles at different concentrations. In previous reports, 
the concentration of different aggregates was usually expressed as 
a function of the initial soluble protein concentration and not as 
a real concentration of particles in solution.155
Conclusions
Increasing evidence indicates that aggregation of α-synuclein is 
a critical factor in the etiology of PD and other synucleinopathies. 
Several studies have focused on explaining the structural features 
of α-synuclein and the mechanism leading to its aggregation 
and fibrillization. These investigations may explain molecular 
mechanisms occurring in living cells and leading to disease 
development. In vitro aggregation assays are powerful tools 
for studying the mechanisms responsible for the formation 
of different aggregate species of α-synuclein, their structural 
properties and biological functions. Moreover, aggregation assays 
are crucial to develop new drug compounds or novel therapy 
strategies to prevent disease development and progression. Recent 
studies clearly indicate that misfolded α-synuclein aggregates may 
be internalized by cells and propagated in a prion-like manner, 
leading to toxicity. In fact, Watts and collaborators have shown 
that α-synuclein aggregates formed in the brains of MSA patients 
are transmissible in a prion-like fashion.156
Prion-like transmission and propagation of misfolded proteins 
seems to be a process common to several neurodegenerative dis-
orders, not only PD, but also Alzheimer̀ s disease, Huntingtoǹ s 
disease, amyloid lateral sclerosis, and others.
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